Adjuvant and first line chemotherapy use for endometrial cancer
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference38 articles.
1. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group;Aapro;Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.,2003
2. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study;Aghajanian;J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.,2011
3. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer;Aghajanian;Gynecol. Oncol.,2018
4. Endometrial cancer: Molecular markers and management of advanced stage disease;Arend;Gynecol. Oncol.,2018
5. Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis;Bregar;Gynecol. Oncol.,2017
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer;International Journal of Gynecologic Cancer;2024-06-30
2. Endometrial Cancer: 2023 Revised FIGO Staging System and the Role of Imaging;Cancers;2024-05-14
3. Identification of a disulfidptosis‐related prognostic signature for prediction of the effect of treatment in patients with endometrial carcinoma;Cancer Innovation;2024-04-23
4. Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States;Journal of Health Economics and Outcomes Research;2023-11-08
5. Corrigendum to “Adjuvant and first line chemotherapy use for endometrial cancer” [Gynecol. Oncol. Rep. 41 (2022) 101002];Gynecologic Oncology Reports;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3